Predilife (XPAR:ALPRE) Short-Term Debt : €0.69 Mil (As of Jun. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Predilife Short-Term Debt?

Predilife's Short-Term Debt for the quarter that ended in Jun. 2023 was €0.69 Mil.

Predilife's quarterly Short-Term Debt increased from Jun. 2022 (€0.58 Mil) to Dec. 2022 (€0.65 Mil) and increased from Dec. 2022 (€0.65 Mil) to Jun. 2023 (€0.69 Mil).

Predilife's annual Short-Term Debt increased from Dec. 2020 (€0.00 Mil) to Dec. 2021 (€0.35 Mil) and increased from Dec. 2021 (€0.35 Mil) to Dec. 2022 (€0.65 Mil).

Predilife Short-Term Debt Historical Data

The historical data trend for Predilife's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Predilife Short-Term Debt Chart

Predilife Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Short-Term Debt

Get a 7-Day Free Trial

0.35

0.65

Predilife Semi-Annual Data
	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Short-Term Debt	Get a 7-Day Free Trial									-	0.35	0.58	0.65	0.69

Predilife Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Predilife Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Predilife's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Predilife (XPAR:ALPRE) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Predilife SA (XPAR:ALPRE) » Definitions » Short-Term Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

114 rue Edouard Vaillant Espace Maurice Tubiana, Villejuif, Paris, FRA, 94800

Website

https://www.predilife.com

Predilife SA develops solutions of predictive medicine combining proven medical techniques (genetic tests, medical imaging) and mathematical models using a large number of statistical data that could allow each individual to define his risk profile for the occurrence of a large number of serious diseases. The company markets its Mammorisk personalized breast cancer screening solution in Europe and the United States.

Predilife (XPAR:ALPRE) Headlines

No Headlines